Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of
mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only …

Chronic obstructive pulmonary disease (COPD) constitutes a major global health burden
and is the third leading cause of death worldwide. A high proportion of patients with COPD …

Background Use of combinations of long-acting β2 agonists/long-acting muscarinic
antagonists (LABA/LAMA) in patients with chronic obstructive pulmonary disease (COPD) is …

COPD and cardiovascular disease have complicated interrelationships. Further mechanistic
studies may lead to defining better targets for interventions. Education for medical …

Background: Chronic obstructive pulmonary disease (COPD) has significant systemic
manifestations, including cardiovascular morbidity. The main aim of our study was to …

Background Despite potential benefits and widespread prescription of aspirin among
chronic obstructive pulmonary disease (COPD) patients, limited research has investigated …

We read with great interest the meta-analysis recently published in the European
Respiratory Journal by Yang et al.[1] concerning the risk of major adverse cardiovascular …

COPD management mainly aims at relieving symptoms, and improving exercise tolerance
and quality of life, as well as preventing exacerbations, disease progression and mortality …

While not being appropriate for acute attacks, one beneficial attribute of bambuterol is that it
is a long-acting beta adrenoceptor agonist, making it feasible to use in chronic illnesses to …

Conclusions:• Since the last P & T Committee review of inhalers for asthma and COPD in
December 2022, 3 high-quality systematic reviews1-3 and 2 high-quality guidelines4, 5 …